Placental Aromatase Deficiency: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(105 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{CMG}} {{AE}}
{{SI}}
{{CMG}} {{AE}} Rupashi; {{Jose}}
==Overview==
==Overview==
Aromatase deficiency is an autosomal recessive disorder in which there is a decrease or absence in the level of [[Aromatase|aromatase]] in the body which leads to impairment in the conversion of androgens to estrogen. This is due to a genetic mutation in the CYP19A1, a subtype of [[https://www.wikidoc.org/index.php/Cytochrome_P450|Cytochrome P450]]. Patient affected by this disease typically presents with maternal virilization, amenorrhea in puberty in females. Males are rarely affected.
Aromatase deficiency is an [[autosomal recessive]] disorder in which there is a decrease or absence in the level of [[Aromatase|aromatase]] in the body, which leads to impairment in the conversion of androgens to estrogen. This is due to a [[genetic mutation]] in the [[CYP19A1]], a subtype of [[cytochrome P450]]. Patients affected by this disease typically present with maternal [[virilization]], [[amenorrhea]] during puberty in females. Males are rarely affected.


==[[Placental aromatase deficiency historical perspective|Historical Perspective]]==
==[[Placental aromatase deficiency historical perspective|Historical Perspective]]==
The evidence of the disease goes back to year 1991, when the first case of aromatase deficiency occurred <ref>Shouzu M, Akasofu K, Harada T, Kubota Y (March 1991). "A new cause of female pseudohermaphroditism: placental aromatase deficiency". J. Clin. Endocrinol. Metab. 72 (3): 560–566. doi:10.1210/jcem-72-3-560. PMID 1825497.</ref>. Most of the cases were that of women during the third trimester of pregnancy presenting with maternal virilization resulting in hirsutism and acne.
*The evidence of the disease goes back to the year of 1991, when the first case of aromatase deficiency occurred in a 24-year old primigravida and the female fetus showed pseudohermaphroditism.<ref name="pmid1825497">{{cite journal| author=Shozu M, Akasofu K, Harada T, Kubota Y| title=A new cause of female pseudohermaphroditism: placental aromatase deficiency. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 72 | issue= 3 | pages= 560-6 | pmid=1825497 | doi=10.1210/jcem-72-3-560 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1825497 }} </ref>
*The majority of affected individuals were women during the third trimester of [[pregnancy]] manifesting with maternal [[virilization]] resulting in [[hirsutism]] and [[acne]].
 
==Classification==
 
*There is no established system for the [[classification]] of placental aromatase deficiency.


==[[Placental aromatase deficiency pathophysiology|Pathophysiology]]==
==[[Placental aromatase deficiency pathophysiology|Pathophysiology]]==
CYP19A1 gene is responsible for the production of enzyme [[Aromatase|aromatase]], which converts androgens to different forms of estrogen . Estrogen is involved in sexual development in females prior to birth and the levels peak during pregnancy. Mutation in CYP19A1 gene leads to deficiency or absence of activity of aromatase <ref>[https://medlineplus.gov/genetics/condition/aromatase-deficiency/#references Aromatase Deficiency] 18 August, 2020. Retrieved 13 June 2021 </ref>. As a result, there is decrease in production of estrogen due to lack of conversion of androgens to estrogen and increase in testosterone and androstenedione levels. In pregnant women , excess androgens cross the placenta and enter into the maternal circulation leading to virilization. Female fetuses who are affected have ambiguous genitalia while males develop osteoporosis.
*Placental aromatase deficiency is a rare [[autosomal recessive]] disorder.
*The [[CYP19A1]] [[gene]] is responsible for the production of the enzyme [[Aromatase|aromatase]], which converts androgens to different forms of [[estrogen]].
*[[Mutation]] is inherited in an [[autosomal recessive]] mode.
*[[Estrogen]] is involved in [[sexual]] development in females prior to birth and the levels peak during [[pregnancy]]. [[Mutation]] in the [[CYP19A1]] [[gene]] leads to deficiency or absence of activity of aromatase.
*As a result, there is a decrease in the production of [[estrogen]] due to lack of conversion of androgens to [[estrogen]] and an increase in [[testosterone]] and androstenedione levels.
*In pregnant women, excess androgens cross the [[placenta]] and enter into the maternal [[circulation]] leading to [[virilization]]. Female fetuses who are affected have [[ambiguous genitalia]] while males develop [[osteoporosis]].<ref name="pmid27086564">{{cite journal| author=Akçurin S, Türkkahraman D, Kim WY, Durmaz E, Shin JG, Lee SJ| title=A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans. | journal=J Clin Res Pediatr Endocrinol | year= 2016 | volume= 8 | issue= 2 | pages= 205-10 | pmid=27086564 | doi=10.4274/jcrpe.2761 | pmc=5096477 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27086564  }} </ref>


==[[Placental aromatase deficiency causes|Causes]]==
==[[Placental aromatase deficiency causes|Causes]]==
CYP19A1 gene mutation primarily causes Placental Aromatase Deficiency and the placenta is not capable of converting androgenic precursors of estrogen to estradiol. Mutations on exons 3,5 and 9 have been reported. Studies suggest that it is more prevalent in consanguinous marriages and both are heterozygous carriers of the mutation.


==Differential Diagnosis==
*[[CYP19A1 gene]] [[mutation]] primarily causes placental aromatase deficiency and the placenta is not capable of converting androgenic precursors of [[estrogen]] to estradiol. [[Mutations]] on [[exons]] 3,5, and 9 have been reported.<ref name="pmid23093430">{{cite journal| author=Ludwikowski B, Heger S, Datz N, Richter-Unruh A, González R| title=Aromatase deficiency: rare cause of virilization. | journal=Eur J Pediatr Surg | year= 2013 | volume= 23 | issue= 5 | pages= 418-22 | pmid=23093430 | doi=10.1055/s-0032-1324798 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23093430  }} </ref>
Congenital adrenal hyperplasia can be considered as a differential in female patients.
*Studies suggest that it is more prevalent in consanguineous marriages and both are heterozygous carriers of the [[mutation]].
While, in male patients;
 
* 5 alpha reductase deficiency
==[[Placental aromatase deficiency differential diagnosis|Differentiating Any Disease from other Diseases]]==
  Key differentiating features: It is present exclusively in males (46,XY) and the levels of testosterone and estrogen are normal.
 
* Estrogen resistance syndrome  
*[[Congenital adrenal hyperplasia]] can be considered as a [[differential]] in female [[patients]].<ref name="pmid31801784">{{cite journal| author=Agrawal SS, Chakraborty PP, Sinha A, Maiti A| title=Child with '46, XX' disorder of sex development: clues to diagnose aromatase deficiency. | journal=BMJ Case Rep | year= 2019 | volume= 12 | issue= 12 | pages=  | pmid=31801784 | doi=10.1136/bcr-2019-232575 | pmc=7001710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31801784  }} </ref>
* 46,XY disorder of sex development due to isolated 17, 20 lyase deficiency
*While, in male [[patients]], it should be differentiated from:
* Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency
**[[5 alpha-reductase deficiency]], which the levels of both [[testosterone]] is low to normal and [[dihydrotestosterone]] level is decreased.<ref name="pmid8723114">{{cite journal| author=Sinnecker GH, Hiort O, Dibbelt L, Albers N, Dörr HG, Hauss H | display-authors=etal| title=Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. | journal=Am J Med Genet | year= 1996 | volume= 63 | issue= 1 | pages= 223-30 | pmid=8723114 | doi=10.1002/(SICI)1096-8628(19960503)63:1<223::AID-AJMG39>3.0.CO;2-O | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8723114  }} </ref>
* Congenital hypogonadotropic hypogonadism  
**[[Estrogen resistance syndrome]]
can be considered as the differentials.
**46,XY disorder of sex development due to isolated [[17, 20 lyase deficiency]].
**[[Congenital adrenal hyperplasia]] due to [[cytochrome P450]] oxidoreductase deficiency.
**[[Congenital hypogonadotropic hypogonadism]].
 
==[[Placental aromatase deficiency epidemiology and demographics|Epidemiology and Demographics]]==
 
*The [[prevalence]] of placental aromatase deficiency is unknown.<ref name="pmid24485503">{{cite journal| author=Bulun SE| title=Aromatase and estrogen receptor α deficiency. | journal=Fertil Steril | year= 2014 | volume= 101 | issue= 2 | pages= 323-9 | pmid=24485503 | doi=10.1016/j.fertnstert.2013.12.022 | pmc=3939057 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24485503  }} </ref>
*There are only a few cases that have been described in literature.
* The first case in males was reported in 1995.<ref name="pmid23748068">{{cite journal| author=Baykan EK, Erdoğan M, Özen S, Darcan Ş, Saygılı LF| title=Aromatase deficiency, a rare syndrome: case report. | journal=J Clin Res Pediatr Endocrinol | year= 2013 | volume= 5 | issue= 2 | pages= 129-32 | pmid=23748068 | doi=10.4274/Jcrpe.970 | pmc=3701920 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23748068  }} </ref>
 
==Risk Factors==
*The [[risk factors]] evident with placental aromatase deficiency include [[placental ischemia]] and [[preeclampsia]].<ref name="pmid26444006">{{cite journal| author=Perez-Sepulveda A, Monteiro LJ, Dobierzewska A, España-Perrot PP, Venegas-Araneda P, Guzmán-Rojas AM | display-authors=etal| title=Placental Aromatase Is Deficient in Placental Ischemia and Preeclampsia. | journal=PLoS One | year= 2015 | volume= 10 | issue= 10 | pages= e0139682 | pmid=26444006 | doi=10.1371/journal.pone.0139682 | pmc=4596497 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26444006  }} </ref>
 
==Screening==
*There is insufficient evidence to recommend routine [[screening]] for Placental aromatase deficiency.


==Natural History , Complications and Prognosis==
==Natural History , Complications and Prognosis==
*Placental aromatase deficiency is a rare entity.
*Defective synthesis of [[estrogen]] in aromatase deficiency may result in :
*[[Delayed Puberty]]
*[[Insulin resistance]]
*[[Polycystic ovary syndrome]]<ref name="pmid27086564">{{cite journal| author=Akçurin S, Türkkahraman D, Kim WY, Durmaz E, Shin JG, Lee SJ| title=A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans. | journal=J Clin Res Pediatr Endocrinol | year= 2016 | volume= 8 | issue= 2 | pages= 205-10 | pmid=27086564 | doi=10.4274/jcrpe.2761 | pmc=5096477 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27086564  }} </ref>
*Bone disorders such as [[osteoporosis]]
==Diagnosis==
===Diagnostic Study of Choice===
*There are no established criteria for the [[diagnosis]] of placental aromatase deficiency. The [[diagnosis]] may be made [[clinically]].
*[[Genetic analysis]] and location of a [[mutation]] in the [[CYP19A1]] [[gene]] may be done for the confirmation of the placental aromatase deficiency.<ref name="pmid1371509">{{cite journal| author=Harada N, Ogawa H, Shozu M, Yamada K, Suhara K, Nishida E | display-authors=etal| title=Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency. | journal=J Biol Chem | year= 1992 | volume= 267 | issue= 7 | pages= 4781-5 | pmid=1371509 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1371509  }} </ref>
===History and Symptoms===
*The hallmark of placental aromatase deficiency is maternal [[virilization]]. A positive history of [[hirsutism]], deepening of the voice, and [[cystic acne]] is suggestive of placental aromatase deficiency.<ref name="pmid24485503">{{cite journal| author=Bulun SE| title=Aromatase and estrogen receptor α deficiency. | journal=Fertil Steril | year= 2014 | volume= 101 | issue= 2 | pages= 323-9 | pmid=24485503 | doi=10.1016/j.fertnstert.2013.12.022 | pmc=3939057 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24485503  }} </ref><ref name="pmid18448329">{{cite journal| author=Zirilli L, Rochira V, Diazzi C, Caffagni G, Carani C| title=Human models of aromatase deficiency. | journal=J Steroid Biochem Mol Biol | year= 2008 | volume= 109 | issue= 3-5 | pages= 212-8 | pmid=18448329 | doi=10.1016/j.jsbmb.2008.03.026 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18448329  }} </ref>
===Physical Examination===
*Physical examination of patients with Placental Aromatase Deficiency is usually remarkable for [[virilization]] and masculinization in mother during pregnancy, [[clitoromegaly]], and [[primary amenorrhea]] in girls during childhood and [[puberty]].<ref name="pmid8200927">{{cite journal| author=Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER| title=A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). | journal=J Clin Endocrinol Metab | year= 1994 | volume= 78 | issue= 6 | pages= 1287-92 | pmid=8200927 | doi=10.1210/jcem.78.6.8200927 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8200927  }} </ref>
*Males are usually normal. They may be tall and have reduced bone age.
===Laboratory Findings===
*An elevated concentration of serum [[testosterone]] and reduced levels of [[estrogen]] is diagnostic of placental aromatase deficiency.<ref name="pmid29324451">{{cite journal| author=Mazen I, McElreavey K, Elaidy A, Kamel AK, Abdel-Hamid MS| title=Aromatase Deficiency due to a Homozygous CYP19A1 Mutation in a 46,XX Egyptian Patient with Ambiguous Genitalia. | journal=Sex Dev | year= 2017 | volume= 11 | issue= 5-6 | pages= 275-279 | pmid=29324451 | doi=10.1159/000485278 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29324451  }} </ref>
*In aromatase deficient girls, basal and GnRH-stimulated [[FSH]] levels are elevated.<ref name="pmid24485503">{{cite journal| author=Bulun SE| title=Aromatase and estrogen receptor α deficiency. | journal=Fertil Steril | year= 2014 | volume= 101 | issue= 2 | pages= 323-9 | pmid=24485503 | doi=10.1016/j.fertnstert.2013.12.022 | pmc=3939057 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24485503  }} </ref>
*Urinary levels of [[androgens]] are usually normal or elevated.
===Electrocardiogram===
*There are no [[ECG]] findings associated with placental aromatase deficiency.
===X-ray===
*An [[x-ray]] may be helpful in the [[diagnosis]] of [[osteoporosis]] which manifests mainly in males.<ref name="pmid19707181">{{cite journal| author=Rochira V, Carani C| title=Aromatase deficiency in men: a clinical perspective. | journal=Nat Rev Endocrinol | year= 2009 | volume= 5 | issue= 10 | pages= 559-68 | pmid=19707181 | doi=10.1038/nrendo.2009.176 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19707181  }} </ref> Findings on an x-ray suggestive of [[osteoporosis]] include loss of bone mass, cortical thinning, and minor [[fractures]].
===Echocardiography or Ultrasound===
*Ultrasound may be helpful in the [[diagnosis]] of [[polycystic ovary syndrome]] which occurs as a sequela in female [[patients]].<ref name="pmid27086564">{{cite journal| author=Akçurin S, Türkkahraman D, Kim WY, Durmaz E, Shin JG, Lee SJ| title=A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans. | journal=J Clin Res Pediatr Endocrinol | year= 2016 | volume= 8 | issue= 2 | pages= 205-10 | pmid=27086564 | doi=10.4274/jcrpe.2761 | pmc=5096477 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27086564  }} </ref>
===CT scan===
*There are no [[CT]] scan findings [[associated]] with placental aromatase deficiency.
===MRI===
*There are no [[MRI]] findings [[associated]] with placental aromatase deficiency.
===Other Imaging Findings===
*There are no other imaging findings [[associated]] with placental aromatase deficiency.
===Other Diagnostic Studies===
*There are no other diagnostic studies associated with placental aromatase deficiency.
==Treatment==
===Medical Therapy===
*In [[patients]] with aromatase deficiency, lifetime hormone replacement therapy is mandatory.
*Hormone replacement therapy, like oral conjugated estrogen, may be useful to stimulate pubertal growth spurt, breast development, and induce menstruation in females. This may also lead to the resolution of cystic ovaries and promote bone growth.
*After 14 years of age, the combination [[oral contraceptive]] may be used.<ref name="pmid24485503">{{cite journal| author=Bulun SE| title=Aromatase and estrogen receptor α deficiency. | journal=Fertil Steril | year= 2014 | volume= 101 | issue= 2 | pages= 323-9 | pmid=24485503 | doi=10.1016/j.fertnstert.2013.12.022 | pmc=3939057 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24485503  }} </ref>
*Treatment options for males include transdermal [[estradio]]l that helps in increasing bone mineral density.<ref name="pmid18448329">{{cite journal| author=Zirilli L, Rochira V, Diazzi C, Caffagni G, Carani C| title=Human models of aromatase deficiency. | journal=J Steroid Biochem Mol Biol | year= 2008 | volume= 109 | issue= 3-5 | pages= 212-8 | pmid=18448329 | doi=10.1016/j.jsbmb.2008.03.026 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18448329  }} </ref>
===Surgery===
*[[Surgical]] [[intervention]] may be an option for ambiguous genitalia.<ref name="pmid8530621">{{cite journal| author=Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K| title=Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. | journal=J Clin Endocrinol Metab | year= 1995 | volume= 80 | issue= 12 | pages= 3689-98 | pmid=8530621 | doi=10.1210/jcem.80.12.8530621 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8530621  }} </ref>
===Primary Prevention===
*There are no established measures for the [[primary prevention]] of placental aromatase deficiency.


* Placental aromatase deficiency is a rare entity.
===Secondary Prevention===


As a result of defective synthesis of estrogen AD may result in :
*There are no established measures for the [[secondary prevention]] of placental aromatase deficiency.
* Delayed Puberty
* Insulin resistance
* Polycystic ovarian disorder
* Bone disorders


* In patients with Aromatase deficiency lifetime hormone replacement therapy is mandatory. We can see osteoporosis as an outcome in male patients with late diagnosis, and these skeletal defects tend to remain even after hormonal treatment and sometimes require surgical correction. Moreover, the effects on glucose and lipid metabolism like adiposity and reproductive defects such as infertility are also not corrected by estradiol treatment.
==Reference==
{{Reflist|2}}


== Reference ==
[[Category:Up to Date]]

Latest revision as of 20:15, 27 April 2022

WikiDoc Resources for Placental Aromatase Deficiency

Articles

Most recent articles on Placental Aromatase Deficiency

Most cited articles on Placental Aromatase Deficiency

Review articles on Placental Aromatase Deficiency

Articles on Placental Aromatase Deficiency in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Placental Aromatase Deficiency

Images of Placental Aromatase Deficiency

Photos of Placental Aromatase Deficiency

Podcasts & MP3s on Placental Aromatase Deficiency

Videos on Placental Aromatase Deficiency

Evidence Based Medicine

Cochrane Collaboration on Placental Aromatase Deficiency

Bandolier on Placental Aromatase Deficiency

TRIP on Placental Aromatase Deficiency

Clinical Trials

Ongoing Trials on Placental Aromatase Deficiency at Clinical Trials.gov

Trial results on Placental Aromatase Deficiency

Clinical Trials on Placental Aromatase Deficiency at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Placental Aromatase Deficiency

NICE Guidance on Placental Aromatase Deficiency

NHS PRODIGY Guidance

FDA on Placental Aromatase Deficiency

CDC on Placental Aromatase Deficiency

Books

Books on Placental Aromatase Deficiency

News

Placental Aromatase Deficiency in the news

Be alerted to news on Placental Aromatase Deficiency

News trends on Placental Aromatase Deficiency

Commentary

Blogs on Placental Aromatase Deficiency

Definitions

Definitions of Placental Aromatase Deficiency

Patient Resources / Community

Patient resources on Placental Aromatase Deficiency

Discussion groups on Placental Aromatase Deficiency

Patient Handouts on Placental Aromatase Deficiency

Directions to Hospitals Treating Placental Aromatase Deficiency

Risk calculators and risk factors for Placental Aromatase Deficiency

Healthcare Provider Resources

Symptoms of Placental Aromatase Deficiency

Causes & Risk Factors for Placental Aromatase Deficiency

Diagnostic studies for Placental Aromatase Deficiency

Treatment of Placental Aromatase Deficiency

Continuing Medical Education (CME)

CME Programs on Placental Aromatase Deficiency

International

Placental Aromatase Deficiency en Espanol

Placental Aromatase Deficiency en Francais

Business

Placental Aromatase Deficiency in the Marketplace

Patents on Placental Aromatase Deficiency

Experimental / Informatics

List of terms related to Placental Aromatase Deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Rupashi; José Eduardo Riceto Loyola Junior, M.D.[2]

Overview

Aromatase deficiency is an autosomal recessive disorder in which there is a decrease or absence in the level of aromatase in the body, which leads to impairment in the conversion of androgens to estrogen. This is due to a genetic mutation in the CYP19A1, a subtype of cytochrome P450. Patients affected by this disease typically present with maternal virilization, amenorrhea during puberty in females. Males are rarely affected.

Historical Perspective

  • The evidence of the disease goes back to the year of 1991, when the first case of aromatase deficiency occurred in a 24-year old primigravida and the female fetus showed pseudohermaphroditism.[1]
  • The majority of affected individuals were women during the third trimester of pregnancy manifesting with maternal virilization resulting in hirsutism and acne.

Classification

  • There is no established system for the classification of placental aromatase deficiency.

Pathophysiology

Causes

  • CYP19A1 gene mutation primarily causes placental aromatase deficiency and the placenta is not capable of converting androgenic precursors of estrogen to estradiol. Mutations on exons 3,5, and 9 have been reported.[3]
  • Studies suggest that it is more prevalent in consanguineous marriages and both are heterozygous carriers of the mutation.

Differentiating Any Disease from other Diseases

Epidemiology and Demographics

  • The prevalence of placental aromatase deficiency is unknown.[6]
  • There are only a few cases that have been described in literature.
  • The first case in males was reported in 1995.[7]

Risk Factors

Screening

  • There is insufficient evidence to recommend routine screening for Placental aromatase deficiency.

Natural History , Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

  • The hallmark of placental aromatase deficiency is maternal virilization. A positive history of hirsutism, deepening of the voice, and cystic acne is suggestive of placental aromatase deficiency.[6][10]

Physical Examination

  • Physical examination of patients with Placental Aromatase Deficiency is usually remarkable for virilization and masculinization in mother during pregnancy, clitoromegaly, and primary amenorrhea in girls during childhood and puberty.[11]
  • Males are usually normal. They may be tall and have reduced bone age.

Laboratory Findings

  • An elevated concentration of serum testosterone and reduced levels of estrogen is diagnostic of placental aromatase deficiency.[12]
  • In aromatase deficient girls, basal and GnRH-stimulated FSH levels are elevated.[6]
  • Urinary levels of androgens are usually normal or elevated.

Electrocardiogram

  • There are no ECG findings associated with placental aromatase deficiency.

X-ray

Echocardiography or Ultrasound

CT scan

  • There are no CT scan findings associated with placental aromatase deficiency.

MRI

  • There are no MRI findings associated with placental aromatase deficiency.

Other Imaging Findings

  • There are no other imaging findings associated with placental aromatase deficiency.

Other Diagnostic Studies

  • There are no other diagnostic studies associated with placental aromatase deficiency.

Treatment

Medical Therapy

  • In patients with aromatase deficiency, lifetime hormone replacement therapy is mandatory.
  • Hormone replacement therapy, like oral conjugated estrogen, may be useful to stimulate pubertal growth spurt, breast development, and induce menstruation in females. This may also lead to the resolution of cystic ovaries and promote bone growth.
  • After 14 years of age, the combination oral contraceptive may be used.[6]
  • Treatment options for males include transdermal estradiol that helps in increasing bone mineral density.[10]

Surgery

Primary Prevention

  • There are no established measures for the primary prevention of placental aromatase deficiency.

Secondary Prevention

Reference

  1. Shozu M, Akasofu K, Harada T, Kubota Y (1991). "A new cause of female pseudohermaphroditism: placental aromatase deficiency". J Clin Endocrinol Metab. 72 (3): 560–6. doi:10.1210/jcem-72-3-560. PMID 1825497.
  2. 2.0 2.1 2.2 Akçurin S, Türkkahraman D, Kim WY, Durmaz E, Shin JG, Lee SJ (2016). "A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans". J Clin Res Pediatr Endocrinol. 8 (2): 205–10. doi:10.4274/jcrpe.2761. PMC 5096477. PMID 27086564.
  3. Ludwikowski B, Heger S, Datz N, Richter-Unruh A, González R (2013). "Aromatase deficiency: rare cause of virilization". Eur J Pediatr Surg. 23 (5): 418–22. doi:10.1055/s-0032-1324798. PMID 23093430.
  4. Agrawal SS, Chakraborty PP, Sinha A, Maiti A (2019). "Child with '46, XX' disorder of sex development: clues to diagnose aromatase deficiency". BMJ Case Rep. 12 (12). doi:10.1136/bcr-2019-232575. PMC 7001710 Check |pmc= value (help). PMID 31801784.
  5. Sinnecker GH, Hiort O, Dibbelt L, Albers N, Dörr HG, Hauss H; et al. (1996). "Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency". Am J Med Genet. 63 (1): 223–30. doi:10.1002/(SICI)1096-8628(19960503)63:1<223::AID-AJMG39>3.0.CO;2-O. PMID 8723114.
  6. 6.0 6.1 6.2 6.3 Bulun SE (2014). "Aromatase and estrogen receptor α deficiency". Fertil Steril. 101 (2): 323–9. doi:10.1016/j.fertnstert.2013.12.022. PMC 3939057. PMID 24485503.
  7. Baykan EK, Erdoğan M, Özen S, Darcan Ş, Saygılı LF (2013). "Aromatase deficiency, a rare syndrome: case report". J Clin Res Pediatr Endocrinol. 5 (2): 129–32. doi:10.4274/Jcrpe.970. PMC 3701920. PMID 23748068.
  8. Perez-Sepulveda A, Monteiro LJ, Dobierzewska A, España-Perrot PP, Venegas-Araneda P, Guzmán-Rojas AM; et al. (2015). "Placental Aromatase Is Deficient in Placental Ischemia and Preeclampsia". PLoS One. 10 (10): e0139682. doi:10.1371/journal.pone.0139682. PMC 4596497. PMID 26444006.
  9. Harada N, Ogawa H, Shozu M, Yamada K, Suhara K, Nishida E; et al. (1992). "Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency". J Biol Chem. 267 (7): 4781–5. PMID 1371509.
  10. 10.0 10.1 Zirilli L, Rochira V, Diazzi C, Caffagni G, Carani C (2008). "Human models of aromatase deficiency". J Steroid Biochem Mol Biol. 109 (3–5): 212–8. doi:10.1016/j.jsbmb.2008.03.026. PMID 18448329.
  11. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER (1994). "A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom)". J Clin Endocrinol Metab. 78 (6): 1287–92. doi:10.1210/jcem.78.6.8200927. PMID 8200927.
  12. Mazen I, McElreavey K, Elaidy A, Kamel AK, Abdel-Hamid MS (2017). "Aromatase Deficiency due to a Homozygous CYP19A1 Mutation in a 46,XX Egyptian Patient with Ambiguous Genitalia". Sex Dev. 11 (5–6): 275–279. doi:10.1159/000485278. PMID 29324451.
  13. Rochira V, Carani C (2009). "Aromatase deficiency in men: a clinical perspective". Nat Rev Endocrinol. 5 (10): 559–68. doi:10.1038/nrendo.2009.176. PMID 19707181.
  14. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K (1995). "Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens". J Clin Endocrinol Metab. 80 (12): 3689–98. doi:10.1210/jcem.80.12.8530621. PMID 8530621.